Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:NY Life Names Marketer Not Rated 3.0 Email Routing List Email & Route  Print Print
Friday, March 22, 2002

NY Life Names Marketer

Reported by Sean Hanna, Editor in Chief

New York Life has a new head marketer for its life and annuity operations. Patricia Spencer Favreau, chief marketing officer, was at NY Life as vice president in charge of the Communications Division of the insurer's Agency Department. That department serves roughly 6,800 agents.

* * *


RBC Dain Builds Broker Relationship Team

RBC Dain Correspondent Services, the clearing unit for RBC Dain Rauscher, has hired Kenneth Ackerman, vice president of business development, to build relationships with brokers. He joins the firm from Fleet's US Clearing where he was director of regional sales and marketing. Ackerman will be based in Baltimore. The firm also promoted Craig Gordon to national director of business development, said Michael Kavanagh, director of RBC DCS. Gordon joined the firm from Fidelity as western regional director of business development in 2000.

* * *


OppFunds Lands MAS Trio for Bonds

OppenheimerFunds has snatched a trio of fixed income managers from Morgan Stanley Investment Management, reports Reuters. The team of Angelo Manioudakis, Benjamin Gord and Charles Moon managed $25 billion of investment-grade fixed income securities for Miller, Anderson, Sherrerd (MAS). At OppenheimerFunds they will manage assets for retail mutual funds and institutional clients.

* * *


Fido Creates Biotech Group

Fidelity is taking the collapse of the venture capital market as an opportunity to make lemonade from lemons. The effort features a distinctly Twenty First Century twist with a focus on biotech rather than silicon tech. To spearhead the effort the Boston Behemoth hired David A. Lowe as its new chief scientific officer and executive vice president for its Biosciences Group. Lowe is a former neurobiologist with the US unit of Swiss drug giant Roche Group. Mark Peterson is president of the group and Jason Rhodes a principal. Fidelity has yet to make any investments through the group.

* * *


Advantus Names Stock Analsyt.

Andrew Adams has taken over as Advantus Capital Management's analysts covering health care stocks for the manager's growth, value, and blended investment portfolios and mutual funds. His new title is investment officer. He joined the St. Paul, Minnesota-based firm in 1997. Advantus Capital Management is an affiliate of the Minnesota Life Insurance Company.

* * *


Supreme Court Denies Hearing on 401k Rollover

Defined contribution plan administrators who roll a participant account into a new fund that subsequently under performs the old fund are not at risk. This week the Supreme Court declined to hear the case of Helfrich vs. PNC Bank Kentucky Inc., reported the Bureau of National Affairs. In that case the participant claimed the administrator breached its fiduciary duty by rolling funds into a money market fund rather than the mutual fund the participant had specified. The plaintiff claimed the fund returned only 4 percent compared to 25 percent in the specified fund. The case was appealed from the U.S. Court of Appeals for the Sixth Circuit, which ruled that restitution, not money damages were relevant and that the plan administrator failed to profit from the participant's plan assets.  

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

3.0
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2024: Q2Q1
2023: Q4Q3Q2Q1
2022: Q4Q3Q2Q1
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly




©All rights reserved to InvestmentWires, Inc. 1997-2024
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use